CA2936079C - Diaryl macrocycles as modulators of protein kinases - Google Patents

Diaryl macrocycles as modulators of protein kinases Download PDF

Info

Publication number
CA2936079C
CA2936079C CA2936079A CA2936079A CA2936079C CA 2936079 C CA2936079 C CA 2936079C CA 2936079 A CA2936079 A CA 2936079A CA 2936079 A CA2936079 A CA 2936079A CA 2936079 C CA2936079 C CA 2936079C
Authority
CA
Canada
Prior art keywords
fluoro
ethenopyrazolo
tetrahydro
methy1
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
CA2936079A
Other languages
English (en)
French (fr)
Other versions
CA2936079A1 (en
Inventor
Jingrong Jean Cui
Yishan LI
Evan W. ROGERS
Dayong Zhai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of CA2936079A1 publication Critical patent/CA2936079A1/en
Application granted granted Critical
Publication of CA2936079C publication Critical patent/CA2936079C/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2936079A 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases Active 2037-01-23 CA2936079C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461931506P 2014-01-24 2014-01-24
US61/931,506 2014-01-24
US201462049326P 2014-09-11 2014-09-11
US62/049,326 2014-09-11
US201562106301P 2015-01-22 2015-01-22
US62/106,301 2015-01-22
PCT/US2015/012597 WO2015112806A2 (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases

Publications (2)

Publication Number Publication Date
CA2936079A1 CA2936079A1 (en) 2015-07-30
CA2936079C true CA2936079C (en) 2022-07-19

Family

ID=53682127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2936079A Active 2037-01-23 CA2936079C (en) 2014-01-24 2015-01-23 Diaryl macrocycles as modulators of protein kinases

Country Status (35)

Country Link
US (7) USRE50634E1 (pl)
EP (6) EP3572416B1 (pl)
JP (5) JP6490713B2 (pl)
KR (1) KR102402179B1 (pl)
CN (3) CN110317213B (pl)
AP (1) AP2016009383A0 (pl)
AU (2) AU2015209239C1 (pl)
CA (1) CA2936079C (pl)
CL (1) CL2016001876A1 (pl)
CY (3) CY1121850T1 (pl)
DK (3) DK3572416T3 (pl)
EA (2) EA031863B1 (pl)
ES (3) ES2976459T3 (pl)
FI (2) FI3636649T3 (pl)
FR (1) FR25C1013I2 (pl)
HR (3) HRP20221518T1 (pl)
HU (4) HUE060554T2 (pl)
IL (2) IL246860B (pl)
LT (4) LT3636649T (pl)
MX (2) MX392904B (pl)
MY (1) MY193524A (pl)
NL (1) NL301322I2 (pl)
NO (1) NO2025015I1 (pl)
NZ (2) NZ722375A (pl)
PE (1) PE20160931A1 (pl)
PH (1) PH12016501463A1 (pl)
PL (3) PL3636649T3 (pl)
PT (3) PT3572416T (pl)
RS (3) RS59059B1 (pl)
SG (2) SG11201605929RA (pl)
SI (3) SI3572416T1 (pl)
SM (3) SMT202400175T1 (pl)
UA (1) UA121206C2 (pl)
WO (1) WO2015112806A2 (pl)
ZA (2) ZA201604654B (pl)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
HUE061448T2 (hu) 2014-11-16 2023-07-28 Array Biopharma Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
WO2016196671A1 (en) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methods of diagnosing and treating cancer
ES2864839T3 (es) * 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) * 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
FI3733187T3 (fi) * 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
US11278521B2 (en) 2015-12-15 2022-03-22 University Of South Florida GAS5 binding compounds, formulations, and uses thereof
ES2987474T3 (es) 2016-04-04 2024-11-15 Loxo Oncology Inc Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
ES2836222T3 (es) 2016-05-18 2021-06-24 Loxo Oncology Inc Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN107586796B (zh) * 2017-07-20 2021-08-06 暨明医药科技（苏州）有限公司 (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法
US11286264B2 (en) * 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
TW201927790A (zh) * 2017-11-10 2019-07-16 美商安捷克斯製藥公司 作為trk激酶抑制劑之巨環化合物及其用途
LT3728271T (lt) * 2017-12-19 2022-12-12 Turning Point Therapeutics, Inc. Makrocikliniai junginiai, skirti ligų gydymui
WO2019126122A1 (en) 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
US11453672B2 (en) 2017-12-22 2022-09-27 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
WO2019144885A1 (zh) * 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
CN111511749B (zh) * 2018-01-30 2022-02-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
BR112020019399A2 (pt) * 2018-03-28 2021-01-05 Fochon Pharmaceuticals, Ltd. Compostos macrocíclicos como inibidores de trk quinases
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
US11358973B2 (en) 2018-04-16 2022-06-14 Shenzhen Targetrx, Inc. Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity
WO2019206069A1 (zh) * 2018-04-25 2019-10-31 北京普祺医药科技有限公司 一种二芳基巨环化合物、药物组合物以及其用途
WO2019210835A1 (zh) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN110627812B (zh) 2018-06-25 2022-10-11 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN110950889B (zh) * 2018-09-27 2022-04-05 北京赛林泰医药技术有限公司 一种多靶点激酶抑制剂及其制备方法和用途
CN112955453B (zh) * 2018-09-29 2022-04-19 山东绿叶制药有限公司 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
CN111171049B (zh) * 2018-11-09 2021-06-04 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂及其用途
CN113166155A (zh) * 2018-11-09 2021-07-23 山东轩竹医药科技有限公司 大环类酪氨酸激酶抑制剂及其用途
EP3883573B1 (en) * 2018-11-19 2024-07-31 Dana-Farber Cancer Institute, Inc. Macrocyclic inhibitors of dyrk1a
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3898615A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
CN111592541B (zh) * 2019-02-21 2021-09-10 山东轩竹医药科技有限公司 大环类激酶抑制剂及其用途
CA3132632A1 (en) * 2019-03-11 2020-09-17 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
AU2020247990A1 (en) * 2019-03-26 2021-11-11 Ventyx Biosciences, Inc. TYK2 pseudokinase ligands
US12410191B2 (en) * 2019-05-21 2025-09-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
US20220411439A1 (en) * 2019-06-19 2022-12-29 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
AU2020296918A1 (en) * 2019-06-21 2022-02-17 Janssen Pharmaceutica Nv Macrocyclic inhibitors of MCL-1
CN113773335B (zh) * 2019-06-21 2024-12-03 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
EP3999504A1 (en) 2019-07-16 2022-05-25 MyoKardia, Inc. Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
WO2021063276A1 (zh) * 2019-09-30 2021-04-08 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
CN114901286B (zh) * 2019-11-27 2024-05-10 特普医药公司 涉及二芳基巨环化合物的组合疗法
US11666574B2 (en) 2019-11-27 2023-06-06 Turning Point Therapeutics, Inc. Combination therapy involving diaryl macrocyclic compounds
AU2020395136A1 (en) * 2019-12-03 2022-07-07 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
EP4069369A4 (en) 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE
IL294214B2 (en) 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods for using them
CN113045587A (zh) * 2019-12-27 2021-06-29 成都倍特药业股份有限公司 一种大环结构化合物的晶型及其制备方法
CN113135938B (zh) * 2020-01-19 2022-06-14 山东轩竹医药科技有限公司 取代的大环类酪氨酸激酶抑制剂及其用途
IL295938A (en) * 2020-03-02 2022-10-01 Turning Point Therapeutics Inc Therapeutic uses of macrocyclic compounds
PE20230609A1 (es) 2020-05-04 2023-04-13 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso
EP4148055A4 (en) * 2020-05-08 2023-10-11 Shandong Xuanzhu Pharma Co., Ltd. CRYSTAL FORM OF A MACROCYCLIC TYROSINE KINASE INHIBITOR AND PROCESS FOR PRODUCTION THEREOF
JP2023528907A (ja) * 2020-06-04 2023-07-06 シンノハブ ファーマシューティカル カンパニー，リミティド 大環状構造を有する化合物及びその使用
EP4178958A4 (en) * 2020-07-10 2024-12-11 Blossomhill Therapeutics, Inc. MACROCYCLES AND THEIR USE
JP2023541047A (ja) 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN113754657B (zh) * 2021-09-22 2023-01-17 广州白云山医药集团股份有限公司白云山制药总厂 大环类化合物的晶型及其制备方法和应用
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
CN116514813A (zh) * 2021-12-31 2023-08-01 轩竹生物科技股份有限公司 酪氨酸激酶抑制剂及其中间体的制备方法
AU2023204770A1 (en) * 2022-01-05 2024-07-18 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as kinase inhibitors
CN115746023B (zh) * 2022-10-27 2024-08-09 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
WO2025059027A1 (en) 2023-09-11 2025-03-20 Schrödinger, Inc. Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
WO2025077773A1 (zh) * 2023-10-10 2025-04-17 上海翊维康医药有限责任公司 新的i型拓扑异构酶抑制剂及其制备方法和用途
WO2025217347A2 (en) 2024-04-11 2025-10-16 Bristol-Myers Squibb Company Process of preparing repotrectinib
WO2025235733A1 (en) * 2024-05-09 2025-11-13 Blossomhill Therapeutics, Inc. Bis-bicycloheteroaryl macrocycles and their use

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
EP0281841B1 (de) 1987-03-07 1990-11-14 Bayer Ag Verfahren zur Herstellung von 5-Amino-4,6-dihalogenpyridinen
AU679053B2 (en) 1993-03-25 1997-06-19 Pharmacia & Upjohn Company Indoletetralins having dopaminergic activity
NO308798B1 (no) 1993-12-07 2000-10-30 Lilly Co Eli Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
FR2793791B1 (fr) 1999-05-19 2002-01-25 Univ Paris 7 Denis Diderot Nouveaux composes inhibiteurs specifiques de phospholipases a2
MXPA03000906A (es) 2000-07-31 2005-02-24 Hoffmann La Roche Derivados de piperazina.
JP2004526676A (ja) 2000-12-08 2004-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド キナーゼ阻害剤として有用な大員複素環式化合物
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7970766B1 (en) 2007-07-23 2011-06-28 Google Inc. Entity type assignment
US8815872B2 (en) * 2008-09-08 2014-08-26 Merck Patent Gmbh Macrocyclics pyrimidines as aurora kinase inhibitors
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
CN102271515B (zh) 2008-10-31 2014-07-02 健泰科生物技术公司 吡唑并嘧啶jak抑制剂化合物和方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US20110029480A1 (en) * 2009-08-03 2011-02-03 IntelliCubes, Inc. Method of Compiling Multiple Data Sources into One Dataset
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
EP2509980A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Heterocyclic compounds containing an indole core
US9073926B2 (en) 2009-12-07 2015-07-07 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
NZ604708A (en) * 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2508607A1 (en) * 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2744331A4 (en) 2011-08-19 2015-01-21 Merck Sharp & Dohme METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN
WO2013045701A2 (en) 2011-09-29 2013-04-04 L'oreal Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor
WO2013045702A2 (en) 2011-09-29 2013-04-04 L'oreal Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
GB2495134B (en) 2011-09-30 2014-06-11 Tridonic Uk Ltd Power supply apparatus
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
HUE034118T2 (en) * 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
RU2014140739A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
EP2834243B1 (en) 2012-03-09 2018-04-25 Lexicon Pharmaceuticals, Inc. PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
EP2645540A1 (de) 2012-03-28 2013-10-02 Siemens Aktiengesellschaft Glimmschutzwerkstoff für eine elektrische Maschine
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2014118186A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
EP2989082A1 (en) 2013-04-23 2016-03-02 LEK Pharmaceuticals d.d. Novel synthetic process to 8-chloro-1-methyl-benzo[d]azepine, novel intermediates and the production thereof
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
PL3636649T3 (pl) 2014-01-24 2024-05-06 Turning Point Therapeutics, Inc. Diaryle makrocykliczne jako modulatory kinaz białkowych
WO2016070241A1 (en) 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
CA2971024C (en) 2014-12-15 2023-09-26 Handok Inc. Fused ring heteroaryl compounds and their use as trk inhibitors
CN107531666A (zh) 2015-02-20 2018-01-02 里格尔药品股份有限公司 Gdf‑8抑制剂
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
EA201792421A1 (ru) 2015-05-05 2018-05-31 Байер Фарма Акциенгезельшафт Амидозамещенные производные циклогексана
CN108289610A (zh) 2015-06-29 2018-07-17 Q-科雷医疗有限公司 用于感测和分析医疗装置的导管内的流体和其中的气泡的特性的方法、电路、装置、组件、系统和相关联的计算机可执行代码
ES2864839T3 (es) 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
JP6917974B2 (ja) 2015-07-06 2021-08-11 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ジアリール大環状多形
FI3733187T3 (fi) 2015-07-21 2024-12-18 Turning Point Therapeutics Inc Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa
CN108697708A (zh) 2015-10-26 2018-10-23 洛克索肿瘤学股份有限公司 Trk抑制剂抗性癌症中的点突变以及与此相关的方法
BR112018067775B1 (pt) 2016-03-04 2024-02-15 Vanderbilt University Compostos inibidores de mcl-1 indol substituídos, composição farmacêutica compreendendo ditos compostos e usos terapêuticos dos mesmos
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
US11384150B2 (en) 2016-12-14 2022-07-12 Development Center For Biotechnology Antibody-drug conjugates and uses thereof
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
HUE066590T2 (hu) 2024-08-28
JP2021063121A (ja) 2021-04-22
DK3097107T3 (da) 2019-07-08
HK1231407A1 (zh) 2017-12-22
LTPA2025513I1 (pl) 2025-04-25
CY2025009I2 (el) 2026-02-25
CN110317213B (zh) 2022-10-18
US10246466B2 (en) 2019-04-02
PH12016501463B1 (en) 2017-02-06
ES2933350T3 (es) 2023-02-06
US20200216465A1 (en) 2020-07-09
IL246860A0 (en) 2016-08-31
JP6490713B2 (ja) 2019-03-27
LT3636649T (lt) 2024-04-10
PL3636649T3 (pl) 2024-05-06
US10618912B2 (en) 2020-04-14
MX392904B (es) 2025-03-24
CY1125786T1 (el) 2026-02-25
CY2025009I1 (el) 2026-02-25
IL268820A (en) 2019-10-31
CN110317214A (zh) 2019-10-11
EP3097107A4 (en) 2017-08-09
AU2015209239C1 (en) 2026-02-05
MY193524A (en) 2022-10-18
UA121206C2 (uk) 2020-04-27
HUS2500016I1 (hu) 2025-04-28
SG10202000191YA (en) 2020-03-30
NZ722375A (en) 2022-11-25
NZ761094A (en) 2023-02-24
JP2017503867A (ja) 2017-02-02
JP2019104748A (ja) 2019-06-27
HRP20240503T1 (hr) 2024-07-05
CY1121850T1 (el) 2020-07-31
MX2020001360A (es) 2020-03-20
DK3636649T3 (da) 2024-05-21
SMT202300008T1 (it) 2023-03-17
PT3097107T (pt) 2019-07-19
JP2023179539A (ja) 2023-12-19
AU2015209239B2 (en) 2019-09-12
HRP20191283T1 (hr) 2019-10-18
EP3097107B1 (en) 2019-04-17
US9714258B2 (en) 2017-07-25
KR102402179B1 (ko) 2022-05-25
PT3572416T (pt) 2022-12-06
AP2016009383A0 (en) 2016-08-31
ZA202004100B (en) 2023-12-20
FR25C1013I2 (fr) 2026-01-16
WO2015112806A3 (en) 2015-11-12
ZA201604654B (en) 2020-10-28
IL268820B (en) 2021-10-31
KR20160111395A (ko) 2016-09-26
EP3636650A1 (en) 2020-04-15
EA201892241A1 (ru) 2019-02-28
EP4338739A2 (en) 2024-03-20
RS65417B1 (sr) 2024-05-31
HRP20221518T1 (hr) 2023-02-17
SMT201900388T1 (it) 2019-09-09
SI3097107T1 (sl) 2019-08-30
USRE50634E1 (en) 2025-10-14
US12404281B2 (en) 2025-09-02
EP3636649A1 (en) 2020-04-15
NO2025015I1 (no) 2025-03-13
US20170002023A1 (en) 2017-01-05
CL2016001876A1 (es) 2017-02-03
LT3097107T (lt) 2019-07-25
IL246860B (en) 2019-09-26
CN106170289B (zh) 2019-07-23
RS59059B1 (sr) 2019-08-30
US20240140964A1 (en) 2024-05-02
CA2936079A1 (en) 2015-07-30
US20190169207A1 (en) 2019-06-06
LT3572416T (lt) 2022-12-27
NL301322I2 (nl) 2025-05-27
EA201691492A1 (ru) 2017-06-30
EP3572416A1 (en) 2019-11-27
FIC20250015I1 (sv) 2025-03-20
EP3636649B1 (en) 2024-02-14
SMT202400175T1 (it) 2024-07-09
AU2015209239A1 (en) 2016-07-14
HUE045208T2 (hu) 2019-12-30
PT3636649T (pt) 2024-04-09
SI3572416T1 (sl) 2023-02-28
EP3636648A1 (en) 2020-04-15
WO2015112806A2 (en) 2015-07-30
CN106170289A (zh) 2016-11-30
EP3572416B1 (en) 2022-09-21
EP4338739A3 (en) 2024-05-29
DK3572416T3 (da) 2022-12-12
JP7356546B2 (ja) 2023-10-04
CN110317213A (zh) 2019-10-11
ES2976459T3 (es) 2024-08-01
PH12016501463A1 (en) 2017-02-06
CN110317214B (zh) 2022-11-22
HUE060554T2 (hu) 2023-03-28
RS63829B1 (sr) 2023-01-31
PL3097107T3 (pl) 2020-01-31
PL3572416T3 (pl) 2023-02-27
AU2019279951B2 (en) 2021-08-12
FI3636649T3 (fi) 2024-05-02
SG11201605929RA (en) 2016-08-30
US20220112213A1 (en) 2022-04-14
AU2019279951A1 (en) 2020-01-16
US20170334929A1 (en) 2017-11-23
ES2735729T3 (es) 2019-12-20
JP2022133462A (ja) 2022-09-13
MX2016009588A (es) 2017-05-15
SI3636649T1 (sl) 2024-07-31
FR25C1013I1 (fr) 2025-06-20
EA031863B1 (ru) 2019-03-29
PE20160931A1 (es) 2016-09-21
EP3097107A2 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CA2936079C (en) Diaryl macrocycles as modulators of protein kinases
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
TWI736134B (zh) 作為蛋白質激酶之調節劑的二芳基巨環
HK40109104A (en) Diaryl macrocycles as modulators of protein kinases
HK40028407A (en) Diaryl macrocycles as modulators of protein kinases
HK40028407B (en) Diaryl macrocycles as modulators of protein kinases
BR112016017101B1 (pt) Compostos diaril macrociclos como moduladores das proteínas quinases e sua composição farmacêutica
HK40015633A (en) Diaryl macrocycles as modulators of protein kinases
HK1231407B (zh) 作为蛋白质激酶的调节剂的二芳基巨环
EA041662B1 (ru) Способ ингибирования протеин- или тирозинкиназы в клетке с применением диарильного макроциклического соединения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251204